• Chemical name: 2-{4-[(1Z)-4-chloro-1,2-diphenyl-but-1-en-1-yl]phenoxy}-N,N-dimethylethanamine>
• Formula: C₂₆H₂₈ClNO
• Anabolic activity index: not a steroid
• Androgenic activity index: not a steroid

 

 

FARESTOS – PHARMACOM LABS

50 tabs x 20 mg

 

 

Farestos, featuring the active agent toremifene citrate, is a selective estrogen receptor modulator (SERM) derived from triphenylethylene. Initially patented and approved in Europe in the mid-1990s, toremifene is primarily employed to treat metastatic ER+ breast cancer in postmenopausal women.

 

Benefits:

• Utilized in bodybuilding by men for post-cycle therapy (PCT) to counteract or block effects of excessive estradiol resulting from aromatization of various androgens.
• Particularly effective in restoring endogenous testosterone levels and preventing estrogen-related gynecomastia.
• Stimulates the hypothalamus, prompting the release of gonadotrophic hormones (FSH and LH), essential for spermatogenesis and testosterone secretion from testicles.
• Functions within the hypothalamic-pituitary-testes axis (HPTA), crucial for minimizing post-cycle muscle losses.
• Acts as a true estrogen blocker by binding strongly to estradiol receptors, preventing estradiol from activating them.

 

Usage Information:

• Does not lower overall circulating blood plasma levels of estradiol but blocks its activity in specific tissues.
• Differentiates from aromatase inhibitors by not reducing total circulating levels of estradiol in the body.

 

Side Effects:

• Negative impact on SHBG levels, potentially decreasing cycle efficiency when combating gynecomastia symptoms.
• Less potent than tamoxifen in restoring HPTA and endogenous testosterone production, as demonstrated in studies.

 

Dosage Recommendations:

• For a more effective boost in testosterone production, a dosage range of up to 120 mg per day is suggested.
• Initial week of PCT: 120 mg/day, second week: 100 mg/day, remaining 3–4 weeks: 60 mg/day.
• Individual dosages determined based on blood work results.

 

Administration Advice:

• Timing depends on the type and cycle of steroids used, considering their half-lives.
• Initiate Farestos approximately two weeks after the last injection for cycles ending with long-ester base steroids.
• Begin PCT about three days after the last injection for cycles ending with short-ester base steroids.
• Wait for androgen levels to fall before implementing post-cycle therapy.

 

Additional Information:

• Farestos administration has no specific requirements; it can be taken before, during, or after meals and in the morning or night before bed.
• No need to split up the dosage throughout the day, given toremifene’s half-life of about 5 days, ensuring stable blood levels over an extended period.

For more information about the anabolic steroid Farestos, as well as guidance on usage and mixing steroids, consult with our experienced consultants.